Skip to content

A study of the effect of an Ayurvedic formulation in patients with newly diagnosed Type 2 Diabetes melitus

A Multicenter, Open Label, Randomized, Parallel Group Clinical Study Designed To Examine The Efficacy And Safety Of TLY-001 In Both Kashayam And Kashayam Tablet Form Twice Daily Oral Dose In 150 Patients With Newly Diagnosed Type 2 Diabetes Mellitus Over A Period Of Ninety (90) Days.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2017/04/008288
Enrollment
150
Registered
2017-04-03
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E119- Type 2 diabetes mellitus without complications

Interventions

Intervention1: TLY-001 Kashayam: 15 ml TLY-001 Kashayam to be taken along with 45ml luke warm water, twice daily morning 7 AM and evening 6 PM oral administration in empty stomach for 90 days after

Sponsors

Clinfound Clinical Research Services PvtLtd
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients with FBS >= 130 mg/dl to 2.Patients with BMI Ë? 45 kg/m2 . 3.Newly detected Type 2 Diabetes Mellitus (not more than 1 year). 4.The patient with the ability to understand and provide written informed consent form, which must have been obtained prior to screening. 5.Patients willing to comply with protocol requirements

Exclusion criteria

Exclusion criteria: 1.Patients with Type 1 Diabetes or secondary form of Diabetes 2.Pregnant, breast feeding, or planning a pregnancy. 3.Patient with history of treatment with Insulin 4.Patient with history of treatment with any antihyperglycaemic agent. 5.Active, uncontrolled, or clinically significant diseases or disorders of the heart, lung, kidney, GI tract, or central nervous system. 6.Known to have AIDS or HIV positive.

Design outcomes

Primary

MeasureTime frame
Fasting Blood Sugar and Post Prandial Blood SugarTimepoint: Baseline,Day 30,Day 60,Day 90

Secondary

MeasureTime frame
HbA1CTimepoint: Baseline and Day 90;Lipid ProfileTimepoint: Baseline and Day 90;Liver Function TestTimepoint: Baseline and Day 90;Renal Function TestTimepoint: Baseline and Day 90

Countries

India

Contacts

Public ContactDr Sreejith Sreekumar

CARe-KERALAM Ltd

research@carekeralam.com0480-2735737

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026